Eri L M, Tveter K J
Department of Surgery, Ullevaal University Hospital, Oslo, Norway.
J Urol. 1995 Sep;154(3):923-34.
The clinical and urodynamic effects of oral alpha 1-selective adrenoceptor blockers in the treatment of symptomatic benign prostatic hyperplasia were quantified, and side effects and patient tolerance were assessed.
A total of 29 original reports of placebo controlled clinical trials of alpha-blockers in which results were adequately presented was identified and reviewed, along with additional pertinent literature. We assumed that the efficacy of the different alpha-blockers was basically the same and the weighted average treatment effect was calculated in comparison with placebo.
The average improvement in maximum urine flow rate was 1.5 ml. per second but this rate would probably approach 1.8 to 1.9 ml. per second if all dosages had been titrated up to the highest level tolerated. Overall symptom score decreased by 14% and residual urine volume decreased by 29%. A slight decrease in detrusor pressure during voiding was suggested.
alpha-Blockers were beneficial in the treatment of benign prostatic hyperplasia. Tolerance to treatment appeared to develop in a large proportion of patients after 6 months of therapy. However, for patients who benefit from long-term use of alpha-blockers effective treatment might be maintained for years.
对口服α1选择性肾上腺素能受体阻滞剂治疗有症状良性前列腺增生的临床及尿动力学效果进行量化，并评估副作用及患者耐受性。
确定并回顾了29篇关于α受体阻滞剂安慰剂对照临床试验的原始报告，这些报告结果呈现充分，同时还参考了其他相关文献。我们假定不同α受体阻滞剂的疗效基本相同，并计算与安慰剂相比的加权平均治疗效果。
最大尿流率平均改善1.5毫升/秒，但如果所有剂量都滴定至耐受最高水平，该速率可能接近1.8至1.9毫升/秒。总体症状评分下降14%，残余尿量下降29%。提示排尿时逼尿肌压力略有下降。
α受体阻滞剂对良性前列腺增生的治疗有益。治疗6个月后，很大一部分患者似乎会产生治疗耐受性。然而，对于受益于长期使用α受体阻滞剂的患者，有效治疗可能维持数年。
